Quinn机会伙伴在Halozyme股份中购买598K美元, Quinn Opportunity Partners buys $598K in Halozyme shares amid 21.8% Q4 stock rise and earnings beat.

Quinn机会伙伴有限责任公司最近购买了价值598 000美元的Halozyme治疗公司股份,反映出生物制药公司第四季度股价上涨21.8%。 Quinn Opportunity Partners LLC recently bought $598,000 worth of Halozyme Therapeutics, Inc. shares, reflecting the biopharmaceutical company's 21.8% stock price increase in the fourth quarter. Halozyme也超过了预期收入,每股1.19美元,比预测高出0.02美元。 Halozyme also surpassed earnings expectations, reporting $1.19 per share, $0.02 above forecasts. 该公司以酶和装置技术著称,其市场上限为74.4亿美元,P/E比率为17.56。 The company, known for its enzyme and device technology, has a market cap of $7.44 billion and a P/E ratio of 17.56.